Angiogenesis is involved in the pathogenesis of nonrheumatic aortic valve stenosis

Human Pathology

Volumn 34, Issue 8, 2003, Pages 756-763

  Soini, Ylermi ^a   Salo, Tuula ^b   Satta, Jari ^b  

^a UNIVERSITY OF OULU   (Finland)

^b NONE

Author keywords

Angiogenesis; Aortic valve; Nitric oxide synthase; Vascular endothelial growth factor

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PRAVASTATIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ANGIOGENESIS; AORTA VALVE DISEASE; AORTA VALVE REPLACEMENT; AORTA VALVE STENOSIS; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; WESTERN BLOTTING;

EID: 0041386133     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(03)00245-4     Document Type: Article

References (23)

1. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 407:249-257, 2000
2. Pepper MS: Manipulating angiogenesis: From basic science to the bedside. Arterioscler Thromb Vasc Biol 17:605-619, 1997
3. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocrinol Rev 18:4-25, 1997
4. Lamoreaux WJ, Fitzgerald ME, Reiner A, et al: Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinase by microvascular endothelial cells in vitro. Microvasc Res 55;29-42, 1998
5. Ferrara N, Carver-Moore K, Chen H, et al: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439-442, 1996
6. Shalaby F, Rossant J, Yamaguchi TP, et al: Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376:62-66, 1995
7. Jozkowicz A, Cooke JP, Guevara I, et al: Genetic augmentation of nitric oxide increases the vascular generation of VEGF. Cardiovasc Res 51:773-783, 2001
8. Murohara T, Asahara T, Silver M, et al: Nitric oxide synthase modulates angiogenesis in response to tissue ischaemia. J Clin Invest 101:2567-2578, 1998
9. Bonow RO, Carabello B, de Leon AC, et al: ACC/AHA guidelines for the management of patients with valvular heart disease. Executive Summary. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Valvular Heart Disease). J Heart Valve Dis 7:672-707, 1998
10. Warren BA, Yong JLC: Calcification of the aortic valve: Its progression and grading. Pathology 29:360-368, 1997
11. Mohler ER, Adam LP, McClelland P, et al: Bone formation and osteoclast remodelling in calcified cardiac valve: A clinical and pathological analysis [abstract]. J Am Coll Cardiol 31:503A, 1998
12. Satta J, Melkko J, Pòllänen R, et al: Progression of human aortic valve stenosis is associated with tenascin-C expression. J Am Coll Cardiol 39:96-101, 2002
13. Ferrara N: Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77:527-543, 1999
14. Liu RH, Hotchkiss JH: Potential genotoxity of chronically elevated nitric oxide: A review. Mutat Res 339:73-89, 1995
15. Inoue M, Itoh H, Tanaka T, et al: Oxidized LDL regulates vascular endothelial growth factor expression in human macrophages and endothelial cells through activation of peroxisome proliferator-activated receptor-γ. Arterioscl Thromb Vasc Biol 21:560-566, 2001
16. Sunderkotter C, Steinbrink K, & Goebeler M, et al: Macrophages and angiogenesis. J Leuk Biol 55:410-422, 1994
17. Ben-Av P, Crofford LJ, Wilder RL, et al: Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: A potential mechanism for inflammatory angiogenesis. FEBS Lett 372:83-87, 1995
18. Barleon B, Sozzani S, Zhou D, et al: Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87:3336-3343, 1996
19. Clauss M, Gerlach M, Gerlach H, et al: Vascular permeability factor: A tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 172:1535-1545, 1990
20. Neufeld G, Cohen T, Gengrinovitch S, et al: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13:9-22, 1999
21. Bellamy MF, Tajik J, Enriquez-Sarano M: Statin treatment is associated with slower progression of aortic stenosis (AS) independent of cholesterol levels. AHA abstract 116400, 2001
22. Crisby M, Nordin-Fredrikson G, Shah PK, et al: Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human cartoid plaques: Implications for plague stabilization. Circulation 103:926-933, 2001
23. Vincent L, Chen W, Hong L, et al: Inhibition of endothelial cell migration by cerivastatin, an HMG-GoA reductase inhibitor: Contribution to its anti-angiogenic effect. BS Lett 495(3):159-166, 2001